09:41     GOLDIGIT ATOM<02362>-Announcement & Resumption of Trading-4         

    *  Anti-inflammatory       Development stage                              
            2005, commence  2006, launch                                      
      (lornoxicam)    and analgesic   completed                               
    production        to market                                               
                                                                              
    *      Antibiotic      Development stage       2005,                      
    commence        2006, launch                                              
      (Faropenem)             completed       production      to              
    market                                                                    
    *        Antibiotic      Development stage       2005,                    
    commence        2006, launch                                              
      (4AA)           completed       production      to market               
                                                                              
    *        Treatment for cancer    Research works                           
            Plan is to be   Plan is to be                                     
      (Endostatin)    and other angiogenic    submitted                       
    for patent        finalised upon          finalised  upon                 
      diseases        registration    patent is obtained                      
    patent is obtained                                                        
                                                                              
    At present, Beijing Aleznova has made arrangements                        
    to outsource production for four of its products to                       
    an independent manufacturer. The production schedule                      
    for these four products will commence in 2005: *                          
     (lornoxicam) in May, * (4AA)                                             
    in June, * (Montelukast Sodium) in November,                              
    * (Faropenem) in December. To date, it is                                 
    anticipated that Beijing Aleznova will not have to                        
    incur further research and development cost to these                      
    four products as the development stage has been                           
    completed, and there shall be no additional funding                       
    requirement except for cost payable to the                                
    manufacturer which may be financed by credits and                         
    internal resources. It is anticipated that the four                       
    products will generate revenue in 2006.                                   
                                                                              
    NC1205 has just commenced its pre-clinical study and                      
    it is expected that production may only commence in                       
    2009. However, Beijing Aleznova may opt to transfer                       
    the patent or license at the appropriate stage at an                      
    appropriate price. It is anticipated that the total                       
    additional cost of RMB20,000,000 will be required to                      
    complete the development and clinical testing till                        
    2008. It is anticipated that Beijing Aleznova will                        
    use internal resources and/or seek and obtain funds                       
    from banks and other financial institutions in the                        
    PRC to meet the funding requirements.                                     
                                                                              
    Beijing Aleznova has filed patent application                             
    relating to * (Endostatin) the business plan of                           
    which will not be finalised until the patent is                           
    obtained.                                                                 
                                                                              
    Based on the consolidated management accounts of                          
    Golden Crown, as at 31 December 2004, the unaudited                       
    total asset and net assets of Golden Crown was                            
    approximately HKD5,337,000 and HKD1,182,000                               
    respectively. The unaudited net revenue for the year                      
    ended 31 December 2004 was approximately HKD4,739,000,                    
    unaudited profits before and after tax were                               
    approximately HKD663,000 and HKD601,000 respectively.                     
    The accounts of Golden Crown were prepared in                             
    accordance with accounting principles generally                           
    accepted in Hong Kong.                                                    
                                                                              
    REASONS FOR THE ACQUISITION                                               
    As stated in the latest interim report, the Company                       
    continues to operate under a very competitive                             
    environment and there is no sign of recovery in the                       
    foreseeable future. The Company hence has been                            
    looking for investment opportunities that could bring                     
    more return to Shareholders. The Acquisition reflects                     
    the Company's strategy of diversifying the